Basic | |
---|---|
Market Cap | $794.69M |
Price | $19 |
52 Week Range | 8.82-21.86 |
Beta | 0.88 |
Margins | |
Gross Profit Margin | 99.80% |
Operating Profit Margin | -19.60% |
Net Profit Margin | -18.45% |
Valuation (TTM) | |
P/E Ratio | -13.55 |
Price to Sales Ratio | 2.50 |
Price to Book Ratio | 11.05 |
PEG Ratio | 0.10 |
Biotechnology
Healthcare
341
2012-10-11T00:00:00.000Z
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
646 747 1000
10 Hudson Yards, New York, NY, 10001, US
0001270073